Published in final edited form as:

Cell Mol Life Sci. 2015 May ; 72(9): 1679–1698. doi:10.1007/s00018-014-1820-z.

New Paradigms in the Repair of Oxidative Damage in Human Genome:

Mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins

Arijit Dutta^{1,2}, Chunying Yang¹, Shiladitya Sengupta¹, Sankar Mitra^{1,2,*}, and Muralidhar L. Hegde^{1,3,*}

¹Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas 77030

²Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555

³Houston Methodist Neurological Institute, Houston, Texas 77030

Abstract

Oxidized bases in the mammalian genome, which are invariably mutagenic due to their mis-pairing property, are continuously induced by endogenous reactive oxygen species (ROS) and more abundantly after oxidative stress. Unlike bulky base adducts induced by UV and other environmental mutagens in the genome that block replicative DNA polymerases, oxidatively damaged bases such as 5-hydroxyuracil (5-OHU), produced by oxidative deamination of cytosine in the template strand, do not block replicative polymerases and thus need to be repaired prior to replication in order to prevent mutation. Following up our earlier studies, which showed that the Nei endonuclease VIII like 1 (NEIL1) DNA glycosylase, one of five base excision repair (BER)-initiating enzymes in mammalian cells, has enhanced expression during the S-phase and higher affinity for replication fork-mimicking single-stranded (ss) DNA substrates, we recently provided direct experimental evidence for NEIL1's role in replicating template-strand repair. The key requirement for this event, which we named as the 'cow-catcher' mechanism of pre-replicative BER, is NEIL1's non-productive binding (substrate binding without product formation) to the lesion base in ss DNA template to stall DNA synthesis, causing fork regression. Repair of the lesion in re-annealed duplex is then carried out by NEIL1 in association with the DNA replication proteins. NEIL1 (and other BER-initiating enzymes) also interact with several accessory and non-canonical proteins including the heterogeneous nuclear ribonucleoprotein U (hnRNP-U) and Y-box-binding protein 1 (YB-1) as well as high mobility group box 1 protein (HMGB1), whose precise roles in BER are still obscure. In this review, we have discussed the recent advances in our understanding of oxidative genome damage repair pathways with particular focus on the pre-replicative template strand repair and the role of scaffold factors like X-ray repair cross-complementing protein 1 (XRCC1) and Poly [ADP-ribose] polymerase 1 (PARP1) and other accessory proteins guiding distinct BER sub-pathways.

Address correspondence to: Muralidhar L. Hegde (mlhegde@houstonmethodist.org) or Sankar Mitra (smitra2@houstonmethodist.org).

Keywords

Base excision repair; single strand break repair; DNA glycosylase; reactive oxygen species; oxidized DNA bases; pre-replicative repair of oxidized bases; NEIL1; non-canonical proteins

Introduction

The human cell genome is continuously exposed to oxidative damage by reactive oxygen species (ROS), generated both endogenously during metabolic processes, and by exogenous agents including environmental carcinogens and ionizing radiation (IR). Reactive nitrogen species (RNS) NO• generated by NO synthase (NOS) reacts with superoxide anion ($O_2^{\bullet-}$) to produce peroxynitrite (ONOO⁻) and other reactive species [1]. In addition, localized unfolding of chromatin during DNA transactions, particularly replication and transcription, makes DNA more vulnerable to genotoxic agents. This necessitates continuous surveillance of the genome via DNA repair and other DNA damage response proteins by their dynamic interaction not only with the DNA but also with replication and transcription machineries as well as histones, and other cellular components. During the past few decades, repair of oxidative/alkylated base lesions and single-strand breaks (SSBs) via base excision repair (BER) and single-strand break repair (SSBR) pathways, respectively has been extensively studied. More recently, complexities and cross-talks among various repair pathways with replication/transcription machineries and non-canonical proteins are being recognized. In this review, we have focused on the unique BER sub-pathways associated with DNA replication, which is critical for preventing mutations and the roles of some accessory proteins therein. These proteins via their unique ability to involve in specific multi-protein interactions not only enhance BER/SSBR activity but can also regulate cross-talk among repair sub-pathways.

An Overview of Oxidative Genomic Insults in Aerobic Cells

Oxidizing radicals and other compounds, broadly categorized as ROS and RNS, are generated as by-products of respiration and other cellular activities, and also as a result of exposure to chemical pollutants, drugs, tobacco smoke, xenobiotics and IR. ROS include superoxide ($O_2^{\bullet-}$), hydroxyl ($OH^{\bullet}$), peroxy ($RO_2^{\bullet}$), and alkoxy ($RO^{\bullet}$) radicals and non-radical species like peroxynitrite, singlet oxygen (1O_2) and hydrogen peroxide (H_2O_2) [2]. NADPH oxidases (NOX), a group of membrane bound enzymes are major producers of endogenous ROS, and are often activated by multiple cellular stress factors including nutritional deficiency and inflammation [3]. $O_2^{\bullet-}$ is also produced in the inner mitochondrial membrane due to incomplete reduction of O_2 at Complex I (NADH dehydrogenase) and Complex III (cytochrome bc1 complex) in the electron transport chain. $OH^{\bullet}$, the most potent oxidizing agent is generated from $O_2^{\bullet-}$ and H_2O_2 via Haber-Weiss reaction, and also from H_2O_2 by Fenton reaction catalyzed by iron (Fe) and copper (Cu) ions. These essential transition metals are usually sequestered by storage proteins (e.g., ferritin/transferrin for Fe and ceruloplasmin for Cu); however pathological conditions or cellular stress augment their accumulation in the nucleus in the free ionic form resulting in enhanced ROS production [4]. These reactive molecules damage genomic DNA by

oxidizing bases as well as the deoxyribose backbone, leading to various base modifications, formation of apurinic/aprimidinic (AP) sites and strand breaks. The oxidized DNA base lesions induced by ROS include 8-oxo-7,8 dihydroguanine (8-oxo-G), FapyG, thymine glycol, 5-hydroxymethyluracil, 5-formyluracil, 5-methylcytosine, etc. (Fig. 1.A) [5]. In addition to base oxidation, OH[•] also reacts with DNA by H abstraction leading to sugar modifications, with or without cleavage of the pentose ring. Such chemical modifications often generate AP sites or strand breaks with blocked termini that need processing by specific end-processing enzymes prior to repair. Common 3' terminal blocking groups are phosphate, phosphoglycolaldehyde, and phosphoglycerate, while nonligatable 5' termini include OH and phosphodeoxyribose derivatives [6]. RNS include peroxynitrite (ONOO⁻), nitrogen dioxide radical (NO₂[•]), nitroxyl anion (NO⁻), nitrosonium cation (NO⁺), etc. [1] and cause nitration, nitrosation and deamination of DNA bases. NO[•] also indirectly generate exocyclic DNA adducts like 1, N⁶-ethenoadenine (εA) and N²,3-ethenoguanine by reaction of secondary lipid peroxidation products with DNA [7].

BER/SSBR pathways are crucial for the repair of oxidative genome damage

It is commonly postulated that approximately 10⁴ oxidative lesions are produced in the mammalian genome per day, which are efficiently repaired via BER/SSBR proteins, with overlapping reaction steps [8]. Unrepaired base lesions and AP sites could be replicated by DNA translesion synthesis (TLS) polymerases whose replication infidelity could cause point mutations. Spontaneous deamination of C to U, or ROS mediated generation of 5-OHU leads to GC→AT transition mutation during replication via mis-incorporation of A opposite 5-OHU, albeit at a low frequency [9]. 8-oxo-G generated by oxidation of G mis-pairs with A, resulting in GC→TA transversion mutation [10]. Accumulation of such spontaneous mutations likely generated single nucleotide polymorphism (SNPs) observed in the mammalian genome and also could lead to carcinogenic mutations. Furthermore, accumulation of unrepaired SSBs in replicating genome would lead to lethal double-strand breaks (DSBs) [11]. Thus BER/SSBR is an essential process for constant surveillance of the chromatin to prevent mutations from oxidative damage [12].

Initial characterization of minimal BER reactions

Early enzymes of BER were first discovered in *E. coli* – excision of uracil from DNA by a mono-functional DNA glycosylase (later named as uracil-DNA glycosylase or UDG) [13] and demonstration of AP endonuclease activity of endonuclease II [14–16]. Other mono-functional DNA glycosylases, for example SMUG1 removes U and 5-hydroxycytosine (5-OHC) while thymine DNA glycosylase (TDG) removes T in T•G mismatch or T generated by deamination of 5-methyl cytosine. The two-step mechanism involving base excision enzyme, DNA N-glycosylase and endonuclease II mediated strand incision at the generated AP site, was reported for repair of alkylated DNA [17]. The mammalian AP-endonuclease APE1 (ortholog of endonuclease III or Xth in *E. coli*) hydrolyzes the phosphodiester bond 3' to an AP site and produces 3'OH and 5' deoxyribosephosphate (5'dRP) termini [18,19]. Several groups subsequently established that oxidized base-specific glycosylases e.g. 8-oxoguanine DNA glycosylase (OGG1), endonuclease III-like protein 1 (NTH1), NEIL1-3 which are orthologs of *E. coli* Fpg, Nth and Nei, respectively, are bi-functional by having

both base excision and intrinsic AP lyase activity. These enzymes cleave the phosphodiester bond after base removal to generate SSB without requiring AP endonuclease activity [17,20]. OGG1 and NTH1 possess β -elimination lyase activity to generate a 3' phospho α,β -unsaturated aldehyde (3'PUA), chemically called phosphor 4-hydroxypentenol at the strand break along with 5' phosphate (P) terminus, while NEILs carry out β , δ -elimination to form 3'P and 5'P termini [6]. In subsequent end cleaning reactions in mammalian cells, 5'dRP is removed by 5'dRP lyase activity of Pol β followed by incorporation of the correct base to fill the gap. 3'PUA is cleaved by mammalian APE1 to produce the 3'OH terminus. In contrast, the 3'P generated by NEILs is removed by polynucleotide kinase/3'-phosphatase (PNKP) [21]. Thus for oxidized bases, DNA glycosylases that carry out either β -elimination or β,δ -elimination determine the subsequent OGG1/APE1- or NEILs/PNKP-dependent steps, respectively. In the minimal BER pathway, excision of damaged base by OGG1/APE1 or NEILs/PNKP leaves a 1-deoxynucleotide gap whose repair (single nucleotide/short patch BER: SN/SP-BER) involves a DNA polymerase (Pol β), and a DNA ligase (Lig3 α).

The second BER sub-pathway, known as long patch (LP) BER, which involves displacement and resynthesis of 2–8 nts following excision of the base lesion was reported by Dogliotti, Wilson, Klungland and their colleagues [22–24]. While the factors regulating pathway choice between SN- vs. LP-BER is incompletely understood, it was suggested that the latter occurs when Pol β fails to remove the modified or oxidized 5' deoxyribose termini at the strand break [6]. In that case Pol β or Pol δ/ϵ with the help of the replication sliding clamp, proliferating cell nuclear antigen (PCNA) and the clamp loader replication factor C (RFC) displace the damage containing strand and incorporates >2 nts producing a 5'-single stranded flap structure, which is cleaved by flap endonuclease 1 (FEN1). Ligation of the nick in LP-BER is usually mediated by DNA ligase 1 (Lig1) [25]. In addition to the oxidative modification of the 5' sugar moiety, low ATP concentration may also guide the pathway to LP-BER [26].

The end processing, gap filling and ligation reactions in SSBR broadly share proteins and reaction steps with BER, although, additional factors may be involved in SSB recognition and stabilization inducing the SSB sensor PARP1 and scaffold protein XRCC1.

Unique BER sub-pathways for repair during DNA replication and transcription

The unfolding of chromatin required at the replication fork or in the transcription bubble renders DNA more prone to oxidative damage than in condensed chromatin [27,28]. While replication of unrepaired oxidized base lesions, most of which do not block DNA or RNA polymerases, could be mutagenic, their transcription could produce mutant proteins, which could be toxic and/or inactive. Contrary to the bulky adducts which block replication or transcription and are recognized by nucleotide excision repair (NER), recognition and repair of oxidized lesions is not understood. While, there is an urgency to repair these lesions during all DNA transactions, how these are recognized in replicating template or transcribed strand is not clear. Recent studies by us and others have suggested that there are distinct BER sub-pathways for transcriptionally active versus inactive genomes as well as for quiescent versus replicating genome [12,29–32]. Our initial studies showed that both NEILs

are active on bubble and fork-structured DNA substrates that mimic transcription and DNA replication intermediates respectively [32]. However, only NEIL1 is upregulated during the S-phase, based on which we had proposed that NEIL1 is preferentially involved in replication-associated BER (RA-BER) [33] and NEIL2 in transcription-coupled BER (TC-BER) as demonstrated by Hazra and colleagues, where it specifically associates with RNA polymerase II and hnRNP-U [29].

Replication-associated BER is critical for preventing mutations in cycling cells

Template-strand specific pre-replicative versus progeny strand specific post-replicative base damage repair at the replication fork

An unusual feature of oxidized bases is their formation in free nucleotide pool and incorporation in to nascent DNA. In this situation, repair of an incorrect or oxidized base incorporated from the nucleotide pool, immediately after replication has been described as post-replicative repair [34,35]. This ‘progeny strand specific post-replicative repair’ as we would prefer to call it, is also tightly coupled to replication machinery, and has been described for the base incorporated opposite to U or unrepaired 8-oxo-G. When 8-oxo-G is not repaired prior to replication, replicative DNA polymerases (Pol δ/ϵ) may incorporate an A (or the normal base C) opposite the 8-oxo-G, generating an A:8-oxo-G mispair [10]; the mammalian homolog of *E. coli* MutY, MYH excises this mispaired A (Fig. 1.B) [36,37,35]. Similarly, a U:A mis-pair generated during replication of U opposite an A, was shown to be repaired *post-replicative* by UNG2 (nuclear form of UDG) [34]. Both UNG2 and MYH associate with PCNA at the replication foci [38,34], which appears to recruit these glycosylases to the replication sites, facilitating their repair only in the progeny strand [34,35]. Thus these glycosylases interact with the replication machinery, analogous to the classical mis-match repair (MMR) pathway targeting the nascent DNA for post-replicative repair. [35].

However, unlike U, which is mis-incorporated in the progeny strand during replication could be specifically repaired by UNG2, U generated in the template strand due to deamination of C needs to be repaired prior to replication in order to prevent fixation of mutation. Similarly, other oxidative lesions such as 5-OHU and thymine glycol, major substrates of NEIL glycosylases, need to be repaired *pre-replicative* in the template strand in order to maintain genomic integrity. Moreover, increased preference of TLS polymerase Pol η to insert G opposite 5-OHU rather than A also reduces mutagenic potential of 5-OHU [9]. It is thus evident that efficient recognition of these lesions is a prerequisite for efficient pre-replicative repair. The two RA-BER pathways- template strand-associated pre-replicative and progeny strand specific post-replicative BER have been schematically illustrated in Fig. 2.

How can a damaged base be repaired in the single-stranded DNA template prior to replication?

We recently provided direct evidence for NEIL1’s ability to repair oxidized bases by co-opting DNA replication proteins [31]. NEIL1 is present in cells as a component of the DNA replication complex where it carries out surveillance of oxidized bases in the replicating

template. Thus it acts as a ‘cow-catcher’, which is in consistence with its preference for binding to lesions in the ss DNA. However, if it excises oxidized bases and cleaves the template strand in replicating DNA a double-strand break will be generated. In order to avoid this, the ss DNA-binding protein RPA, essential for replication and other DNA transactions, coats the ss DNA template at the replication fork, and inhibits NEIL1’s activity via direct interaction [39]. Further, we observed in *in vitro* reaction that NEIL1 inhibits primer elongation of RPA-coated template by Pol δ , thereby stalling the replication complex at the lesion site. The replication is expected to cause regression of the replication fork causing fork collapse. Re-annealing of the unwound region spanning the lesion by a helicase such as SMARCAL1 or Werner helicase (WRN) [40,41] would then allow repair of the lesion by NEIL1 which is activated by PCNA [33]. Repair synthesis and ligation to seal the nick would be finally carried out by the replicative polymerase Pol δ followed by Lig1 rather than by the canonical BER enzymes Pol β and Lig3 α .

Oxidatively damaged bases such as spiro- and imino-hydantoin and thymine glycol block replication and were shown to be repaired by NEIL1 [42–44]. NEIL1 also functions in repairing replication blocking oxidative genome lesions, as indicated by the inhibition of DNA chain growth in oxidatively stressed NEIL1 deficient cells [31].

Back-up function of NEIL2 in pre-replicative BER

We showed earlier that NEIL2, with similar activity on ss DNA as NEIL1 but without S phase-specific activation, has been linked to repair during transcription [45]. As far as its role in RA-BER is concerned, NEIL2 deficiency alone does not inhibit DNA replication after oxidative stress but enhances replication inhibition in NEIL1 deficient cells. This suggests that in the absence of NEIL1, NEIL2 acts as a ‘relief pitcher’ in removing cytotoxic base lesions from the replicating genome. The broad and overlapping substrate range of oxidized base-specific glycosylases ensures their ability to provide the back-up function when needed [46,47,48]. This is consistent with the observation that mouse mutants and cells lacking individual glycosylases are viable without a strong phenotype [49–51]. However, combined deficiency of two glycosylases strongly increases cancer susceptibility [52–54].

Role of 9-1-1 in repair at stalled replication forks

Upon genotoxic stress, Rad9-Rad1-Hus1 or 9-1-1, a heterotrimeric doughnut-shaped sliding clamp, structurally similar to the replication clamp PCNA [55], and active after DNA damage, is loaded onto DNA by a clamp loader, an RFC variant containing Rad17 which ensures stabilization of the replication fork through Chk1-mediated G2/M arrest [55]. Moreover, 9-1-1 protects stalled replication forks via recruitment of WRN helicase [56,57]. It has also been implicated in BER. While 9-1-1 mediated stimulation of NEIL1, TDG and Pol β [58–60] (but not replicative polymerases Pol α and Pol δ) via physical interaction suggests its direct involvement in SP-BER, stimulation of FEN1 and Lig1 by 9-1-1 suggests its role in repair at stalled replication forks via recruitment of the LP-BER machinery [61,62].

New paradigm: DNA repair complexes are formed via disordered segments

While the minimal BER/SSBR reaction reconstituted *in vitro* requires only four or five enzymes [6], we and others have demonstrated that the *in vivo* repair is highly complex, particularly in the mammals. The basic repair reactions for oxidative genome damage are conserved from the bacteria to humans; however, additional complexities have evolved in higher organisms, which include cross-talk between BER/SSBR with other metabolic pathways in the cell including DNA replication, transcription and cell cycle regulation, as already discussed. In addition, posttranslational modifications of repair proteins e.g. acetylation could also regulate repair [63,64].

Secondary structure prediction of human (and other mammalian) BER enzymes revealed terminal disordered segments, which likely evolved to cope with the complexities of BER/SSBR pathways in higher organisms. Unlike their bacterial orthologs, human DNA glycosylases as well as APE1 have unstructured domains either at the C or the N terminus which are required for the enzymes' critical functions including DNA scanning, protein-protein interactions and subcellular localization [6]. The N terminal tail (1–95 residues) of NTH1 containing nuclear and mitochondrial localization signal sequences also negatively regulates its activity by reducing product dissociation [65]. Human NEIL1 has a 100 residue long noncrystallizable C-terminal segment, which is absent in the bacterial ortholog Nei [66]. During the past few years, our lab has extensively characterized the role of NEIL1's C-terminal tail critical in stabilizing NEIL1's structure and enhancing its overall repair activity through interaction with various conventional and non-canonical BER proteins [67,68]. Based on small angle x-ray scattering (SAXS), fluorescence-based experiments and molecular modeling, we have suggested that the flexible domain, normally packed in folded structure of the core is released, presumably to facilitate 'DNA scanning' and interaction with various BER proteins [69]. As already stated, NEIL1 via its C-terminal tail not only interacts with downstream SN-BER proteins such as Pol β , Lig3 α and XRCC1 but also co-opts LP-BER proteins like FEN-1, PCNA, RPA and Pol δ for pre-replicative repair [31]. In another example, the disordered N-terminal (1–61 amino acids; aa) domain of APE1, which is absent in bacterial prototype Xth was found to be dispensable for its DNA repair-linked AP-endonuclease activity [70,71], but has a critical role in interactions in multiprotein complexes of higher eukaryotes [72–75]. Furthermore, NEIL1-initiated BER activity has been shown to be stimulated by non-canonical DNA repair proteins like WRN [76] and hnRNP-U, an RNA binding protein [77], whose precise *in vivo* role is still not understood.

Involvement of accessory proteins in mammalian BER/SSBR and their emerging role(s) in repair regulation

One unique feature of mammalian BER/SSBR is the involvement of several accessory and non-canonical proteins as observed in *in-cell* repair. While the list of non-canonical proteins implicated in BER/SSBR is growing, here we will discuss the role of scaffold factor XRCC1, SSB sensor PARP1, RNA binding protein hnRNP-U, HMGB1 and YB-1. Such accessory proteins may not only induce structural changes at the damaged site, enabling their rapid detection by conventional damage sensor/repair initiating proteins but also facilitate protein-protein interactions to enhance coordination among the repair steps (Table

1). Through literature-based Ingenuity pathway analysis (IPA) tool we analyzed the interactome of these accessory factors with various chromatin modifying proteins, DNA polymerases, DNA end processing enzymes, ligases, DNA glycosylases and non-homologous end joining (NHEJ) proteins (Fig. 3).

The accessory proteins may also be important in stabilizing large dynamic ‘repairosome’ complexes by providing extended interaction surface area. As observed for early BER/SSBR proteins [78], many of these accessory proteins possess disordered regions either as a terminal appendage or as an internal segment which are commonly involved in protein-protein interactions [79]. We mapped these disordered segments using ‘Predictor Of Naturally Disordered Regions’ (PONDR) algorithm (Fig. 4). The unique structural features of these proteins and how their deficiency or mutation may impact BER/SSBR could be important for establishing their role in cancer and also for exploring them as targets for cancer adjuvant therapy.

Scaffolds and damage sensors

XRCC1 (X-ray cross complementing factor 1)

XRCC1, a scaffold protein with no known enzymatic activity, was shown to co-ordinate BER/SSBR by forming multi-protein repair complexes [80]. It stabilizes Lig3 α and at least 80% of cellular Lig3 α was found to be bound to XRCC1 [81]. Human XRCC1 with 633 residues (~85 kDa) consists of three interactive domains – the N terminal domain (NTD) and two BRCA1 C Terminus (BRCT) domains along with a nuclear localization signal, and each domain has unique interacting partners (Fig. 4).

PONDR analysis reveals two highly disordered segments in XRCC1 located between NTD-BRCT1 (183–315 aa) and BRCT1-BRCT2 (403–538 aa), each of which has unique binding partners. While the first disordered region binds to PCNA, APE1 and OGG1 [82–84], the second has affinity for PNKP [85] (Fig. 4). DNA glycosylases NTH1, NEIL2, OGG1 and MPG interact with the BRCT1 region of XRCC1 [86]. Co-localization of XRCC1 and PCNA in replication-specific foci [82] and role of XRCC1-PCNA interaction in LP-BER [87] suggests XRCC1’s role in replication-associated repair. XRCC1 also interacts with DNA polymerases Rev1 [88], Pol δ and Pol λ [89,90]. While some of these interactions, mostly identified *in vitro* or in tumor cells with ectopic expression may imply their participation in specific repair sub-pathways, the *in vivo* significance is not known.

XRCC1’s NTD (1-183 aa) has a beta sandwich domain that was shown to interact with nicked and gaped DNA substrates as well as with the palm-thumb domains of Pol β near the latter’s active site [91–93]. Biochemical and molecular modeling studies suggest that the NTD via its interaction with both the SSB in DNA and Pol β surrounds the damaged site and performs dual function of protecting the DNA and recruiting the repair enzymes [94]. C12A XRCC1 mutant cells (defective in interaction with Pol β) are hypersensitive to H₂O₂ similar to the XRCC1 null cell lines. This underscores the biological role of XRCC1-Pol β interaction in oxidative stress-induced DNA repair [95]. Thus XRCC1’s scaffolding function is critical in formation of distinct repair complexes, particularly in response to oxidative DNA damage.

PARP (poly ADP ribose polymerase)

The PARP family of proteins includes DNA break sensors (PARP1-3) which synthesize linear and branched chains of poly-ADP ribose (PAR) using NAD⁺ as the substrate, after activation as a result of binding to DNA SSB. These chains are covalently attached to several nuclear proteins including themselves, histones, possibly some SSBR proteins and PARP itself [96]. PARP1 is the first identified member of the PARP family and its exact role in DNA damage response, particularly in base damage repair, is still ambiguous [97], presumably because of its dual role in chromatin unfolding via PARylation of histones [97], and recruitment of XRCC1 at SSB sites [94] to initiate SSBR. PARPs also stimulate apoptosis in a caspase-independent fashion by triggering release of apoptosis inducing factor (AIF), presumably to ensure cell death when the genome damage is beyond repair [98]. PARP1 was also shown to have a role in transcriptional regulation [99].

Human PARP1 is a 113 kDa nuclear protein containing three primary structural domains. It has an N terminal DNA binding domain (DBD) containing two zinc finger motifs (ZnF1 and ZnF2) important for recognition of DNA strand break, an autoPARylation domain (AD) with BRCT motif, and a highly conserved C terminal catalytic domain that carries out mono/poly-ADP-ribosylation. The DBD also contains a bipartite nuclear localization signal (NLS) and a third zinc finger motif (ZnF3), which is not required for DNA binding but promotes structural changes after DNA binding for enzymatic activation [100] and regulates PARP1's role in chromosome unfolding [101]. PARP1's tryptophan-, glycine-, arginine-rich (WGR) domain is conserved among the PARP family members but its function is not yet characterized. It has been suggested that PARP1 remains nonspecifically associated with the chromatin via weak interaction of the ZnF1 motif with the sugar phosphate backbone [102,103]. Upon encountering any discontinuity in the DNA backbone, the DBD engages at the major groove of the damaged site resulting in conformational changes followed by dimerization via DBD. Such DNA break-induced PARP1 dimerization exposes the AD of one molecule to the catalytic domain of the other resulting in its trans-autoPARylation [103]. This facilitates unfolding of the chromatin by negatively charged PAR groups making the damaged site accessible to DNA repair proteins. The bulky mesh of PAR polymer recruits many DNA repair proteins but reduces PARP1's affinity for DNA due to large negative charge density. The turnover of PAR chains is crucial for SSBR and is carried out by poly-ADP-ribose glycohydrolase (PARG) [104]. At SSBs PARP1 recruits XRCC1 via BRCT1 domains, forming XRCC1-PARP1 heterotetramer [105], further facilitating assembly of the BER/SSBR complex. PARP1 also PARylates XRCC1 at LL360/361DD preventing its degradation by poly-ubiquitylation and thus enhancing its retention till the oxidative lesion is repaired [106]. At DSB sites, PARP1 and Ku compete with each other [107], possibly for pathway choice of alternative end joining (Alt-EJ) vs. NHEJ for DSB repair [108,109]. Alt-EJ, which is prevalent in NHEJ deficient conditions, is sensitive to PARP1 inhibitors [108]. We propose that BER/SSBR and Alt-EJ utilize common protein complexes recruited by PARP1 (and/or XRCC1) at secondary DSBs generated at closely localized SSB/base lesions, or an SSB close to replication fork. Moreover, NEIL1 has been shown to stimulate PARP1 while it itself is inhibited by the same through direct physical interaction, which suggests PARP1's direct role in coordination of BER/SSBR in addition to scaffolding function [110]. PARP1 can interfere with NHEJ pathway by inhibiting the

binding of Ku and DNA-dependent serine/threonine protein kinase (DNA-PK) at the DSB and promote homologous recombination (HR), as observed in DT40 and mammalian cells [111]. Recent studies have implicated PARP1's role in Ku-independent alternative DSB repair pathways, through recruiting MRE11 and promoting end resections [112,113]. PARP1 was shown to slow down the replication rate in response to CPT-induced DSBs in mammalian cells and recruit HR-protein RAD51. Thus PARP1 may be involved in HR-coupled replication fork progression [114]. Increased PARP1 activity and degradation of stalled replication fork after PARP inhibition in BRCA2-defective cells have been linked to its role in protecting stalled replication forks through preventing end resection via PAR formation [115]. Pharmacologically blocking PARP1 with small molecule inhibitors has shown to delay SSB and DSB repair and radio-sensitize HR compromised BRCA-deficient breast cancer cells [116,117]; a similar effect was found with PARG depletion due to prevention of removal of PAR scaffold that is necessary for providing access to BER proteins at oxidized DNA lesions [118].

PARP2 is the second member of PARP family which recognizes gaps and flap structures and less efficiently SSB [119]. It has been reported that PARP2's delayed recruitment at SSBs is dependent on PARP1 [120], indicating that PARP2 might be required either in later steps or merely act as a back-up protein for PARP1. Though currently PARP2's role in DSB repair is elusive it has been shown that it suppresses chromosomal translocations [109].

PARP3 has been recently implicated in DSB repair pathway choice. PARP3 promotes NHEJ by stabilizing Ku70-Ku80 heterodimer at DSB and prevent MRE11/CtIP-mediated end-resection required for HR or Alt-EJ [121,122] and recruiting histone chaperone APLF to accelerate XRCC4-ligase IV mediated DSB repair [123].

RNA-binding and other non-canonical proteins in BER

HnRNP-U (heterogeneous ribonucleoprotein-U)

HnRNP-U or scaffold attachment factor (SAF-A), belongs to the family of heterogeneous nuclear RNPs, which have conserved RNA binding domain (RBD), in concert with other essential hnRNPs and have several roles in mRNA metabolism including packaging of nascent mRNAs, alternative splicing and regulation of translation [124]. HnRNPs have been subsequently shown to be involved in DNA metabolism and transcriptional regulation [125]. Post-translational modifications or degradation of various hnRNPs in response to IR-induced damage has implicated these in DSB repair pathway choice [126]. HnRNP-U is phosphorylated by DNA-PK, a key enzyme involved in non-homologous end joining, in response to DSBs induced by etoposide and IR [127]. We recently showed that hnRNP-U, which was previously implicated in TC-BER in collaboration with NEIL2 [128], enhances the 5'-OHU excision activity of NEIL1 by direct interaction, particularly in oxidatively stressed cells, supporting its role in stress-induced enhancement of BER activity [77].

HnRNP-U has two disordered domains – the C-terminal AT-rich SAR (scaffold attachment region) domain that binds to DNA, and the RNA binding N-terminal domain with the arginine-glycine-glycine (RGG) motif. Both of these domains are conserved in the hnRNP family members (Fig. 4). The terminal, disordered segments provide the binding interfaces

for interaction with NEIL1 [77]. While the N-terminal segment is usually sufficient for stimulating NEIL1 activity to the same extent as the full-length protein, the C-terminal segment presumably helps stabilize the interaction. It is also possible that two termini are in close proximity in the native protein. Phosphorylation of hnRNP-U at Ser59 residue by DNA-PK and its association with NHEJ proteins XRCC4 and Ligase IV, first directly linked this otherwise RNA metabolism protein with DNA repair for the first time [129]. HnRNP-U like proteins (hnRNPUL-1/2) have been shown to be binding partners of the DSB sensor and NHEJ factor MRN complex and these also promote recruitment of BLM-helicase at the DSB site [130].

YB-1

YB-1, also a DNA/RNA binding ribonucleoprotein, is primarily involved in transcriptional regulation, mRNA splicing, translation which is attributed to its nucleic acid chaperone activity. The observed association of YB-1 with DNA repair is not completely understood. It is a nucleo-cytoplasmic shuttling protein and its nuclear localization has been linked to multiple drug resistance of malignant cells and resistance to xenobiotics and IR-induced damage [131]. YB-1 was shown to interact via formation of multimeric complexes and to stimulate activity of several DNA proteins involved in BER, NER, MMR and DSB [132,133,72,134]. Increase in the YB-1 level in mammalian cells was also found to correlate with the increase in replication proteins PCNA, DNA topoisomerase II α , and Pol α , indirectly suggesting YB-1's involvement in replication [131].

YB-1 has two intrinsically disordered domains – a long C-terminal domain (CTD) containing alternating clusters of positively and negatively charged amino acid residues (129–324) and an N-terminal alanine/proline-rich domain (APD) (1–51) (Fig 4). YB-1's interaction with DNA repair and other partner proteins is facilitated through type II polyproline (poly(Pro) II) helix conformation in the CTD while the basic residue clusters are responsible for interaction with DNA [135].

YB-1 binds to cisplatin-DNA adducts, AP sites and mismatched DNA with high affinity enhancing localized melting of the duplex DNA and stabilizing the single stranded form, presumably enhancing their repair efficiency. YB-1 has weak 3'→5' exonuclease activity on ss DNA and weak endonuclease activity on duplex DNA. YB-1 stimulates NTH1 and NEIL2 for the release of oxidized bases, and also enhances their AP lyase activity by increasing formation of Schiff base enzyme/substrate intermediates [136,134]. YB-1 as a component of the oxidative stress-induced NEIL2-initiated BER complex, physically interacts with NEIL2, Lig3 α and Pol β [134]. On the other hand, Pestryakov et. al. reported that YB-1, like RPA, suppresses NEIL's AP lyase activity on ss DNA substrates with AP sites while moderately stimulating the same with duplex DNA longer than 48 nts [137]. These could implicate role of YB-1 in transcription/replication-associated repair where it simultaneously prevents induction of breaks at single stranded DNA and enhances repair of oxidized bases in ds DNA. Interestingly, it was recently shown that DNA damage stress-induced proteasome mediated cleavage of YB-1 results in loss of its cytoplasmic retention sequence and thus increases its nuclear accumulation in primary cancer cells. This may contribute to multidrug resistance phenotype of cancer cells [138]. Truncated YB-1 retains

its interaction with DNA damage response proteins γ H2AX, MRE11, Rad50, Ku80 and WRN and in multiprotein repair complexes. YB-1's interaction with PCNA further suggests its role in NER and replication-associated repair [131].

HMGB1

HMGB1 belongs to the family of abundant high mobility group (HMG) of non-histone nuclear proteins whose common nuclear functions are not completely understood. HMGB1 functions as a DNA chaperone in regulating chromatin conformation and transcription. It also has a critical role in inflammation signaling. Furthermore, HMGB1's affinity for bent and distorted non-B DNA structures helps its binding to DNA lesions and inducing further DNA bending for lesion-detection by DNA repair proteins [139]. HMGB1 has been reported to interact with various repair proteins of disparate DNA repair pathways like XPC in NER [140,141]; Ku, DNA-PK and Ligase IV in NHEJ [139,141] and BER enzymes like APE1, Pol β , etc. and enhance their activity and regulates sub-pathway choice [142,139]. Moreover HMGB1 also facilitates unfolding of the chromatin by stimulating chromatin re-modeling factors ACF and CHRAC [143,144], presumably to provide access to the repair proteins at lesion sites buried within the nucleosome.

HMGB1 with a proposed role in sensing oxidatively damaged DNA, contains A and B box domains, each containing 80–90 basic amino acids and share ~30% sequence identity which assigns HMGB1 its affinity for bent, distorted, looped or other non-B DNA structures. After binding to such DNA structures HMGB1 introduces its bulky hydrophobic amino acid residues of the A and B box between successive base pairs in the minor groove resulting in further distortion which is stabilized by basic residues flanking the hydrophobic residues; these structural changes at the DNA lesion enhances recognition by a number of DNA damage response proteins. At the same time, HMGB1 physically interacts with and stimulates some DNA repair proteins, thus enhancing their DNA repair activity. *In vitro* studies have shown affinity of HMGB1 for BER substrate intermediates including AP site, nicked DNA and gapped DNA and with the highest affinity for 5'dRP intermediate. It can form Schiff base intermediate with the 5'dRP which could lead to stable crosslinks [142]. HMGB1 also stimulates activity of APE1 and strand displacement activity of Pol β and FEN1 mediated cleavage of 5–6 nts DNA flap with 5'dRP termini, thus facilitating LP-BER [139]. Thus HMGB1, itself not being a DNA repair protein, can stimulate disparate DNA repair pathways including BER, MMR, NER and NHEJ because of its scaffolding ability [139].

HMGB1 has an acidic C terminal disordered tail (Fig 4), which confers protein stability, enhance its DNA bending properties [145] and regulate repair at nucleosome via its acetylation [146]. Full length HMGB1 has also been shown to inhibit replication, which is diminished upon its acetylation or due to phosphorylation by protein kinase C [147]. The C-terminal truncated mutant does not inhibit replication nor repair of cisplatin-DNA adducts in nucleosomes [146], further suggesting the functional importance of the disordered tail.

Defects in accessory proteins, BER deficiency and human diseases

Because of the role of BER/SSBR in genome surveillance against various endogenous and exogenous oxidative insults, defects in these repair pathways lead to cancer predisposition, aging and various neurodegenerative diseases [148]. Extensive studies have linked defects in or aberrant expression of core and also accessory BER/SSBR proteins to various pathophysiological conditions. For example, XRCC1 deficiency not only sensitizes mammalian cells to diverse DNA damaging agents such as IR, H₂O₂, alkylating agents and CPT, but also causes spontaneous chromosomal aberrations and deletions [94]. Thus, XRCC1 deficiency might increase cancer risk by promoting genomic instability. Certain polymorphic variants of human XRCC1 (e.g., R399G, R194W) have been associated with increased risk of cancer in the ovary, bladder, stomach, pancreatic, colon, skin, lung and of chronic myeloid leukemia [149–154]. Furthermore, it has been reported that XRCC1 is frequently mutated in familial breast and ovarian cancer [155–157,83]. XRCC1 deficiency in breast tumors is associated with an aggressive phenotype and served as an independent predictor of poor clinical outcome [156]. The XRCC1 protein level is significantly downregulated in human gastric cancer tissues relative to the adjacent noncancerous tissues [158]. Perhaps not surprisingly, null mutation of the XRCC1 gene is embryonic lethal in mice. [159,160].

PARP1 expression at both mRNA and protein levels is elevated in a variety of cancers, [161–167]. Furthermore, PARP1 overexpression is frequently correlated with poor outcome in breast cancer and ovarian serous carcinoma [168]. PARP1 overexpression could also be predictive for neoadjuvant chemotherapy [169]. More recently, PARP1 has been shown to have high expression in non-small cell lung cancer cell lines resistant to cisplatin, compared to those cisplatin-susceptible ones, suggesting its correlation with tumor resistance to therapy [170,171]. These studies suggest that PARP1 expression level could be a prognostic biomarker in cancer. PARP-inhibition is emerging as a promising therapeutic regimen, particularly in certain breast cancer patients [169].

BER/SSBR, an attractive anti-cancer target in synthetic lethality regimen

Genomic integrity is critical for health and survival of all organisms, which is maintained by highly evolved DNA repair machinery, involving multiple repair sub-pathways in mammals for both endogenous and induced genotoxic threats. Impaired efficiency in one or more DNA repair pathways is a major driver of carcinogenesis, ageing and age-related chronic disorders. Moreover, robust DNA repair activity, particularly of BER/SSBR, plays a key role in highly pro-oxidant, acidic tumor micro-environment, needed to repair oxidative DNA damage. A large number of nucleotide polymorphic variants in BER/SSBR genes, many of which affect repair activity, have been identified in human population, which are often linked to pathogenicity [172]. Establishing BER/SSBR proteins as markers for cancer susceptibility and prognosis should be an important area. Early studies in this direction should be expanded [173].

Because most anti-cancer drugs and radiation kill cancer cells by inducing DNA damage including various oxidative damage besides DSBs, their efficacy and effective dosage are

governed by specific DNA repair activities in tumor cells. Thus the repair activity could be used as both prognostic and predictive markers for treatment. BER/SSBR is particularly important because their impairment could cause unrepaired SSBs which will be converted in to lethal DSBs in the S phase in continuously multiplying tumor cells. Consequently, DNA repair inhibition and adoption of synthetic lethality (which targets the back up pathway) have recently been shown to have exceptional promise in cancer therapy. However, apart from the use of PARP inhibitors, the efforts to explore BER/SSBR inhibitors have not been successful in patient trial in spite of convincing data confirming their efficacy from *in-cell* and *in vitro* studies. One reason for the failure may be the presence of multiple BER/SSBR sub-pathways, with overlapping and back up roles. Based on the relative success of synthetic lethality of PARP inhibitors with drug/radiation treatment of BRCA-negative breast cancer [174], BER/SSBR inhibitors could also provide effective alternative synthetic lethality strategy. In particular, DNA glycosylases, which we showed to regulate and control the complete repair sub-pathways [68,175,31] and/or DNA ligase III/DNA ligase I, the two key nick-sealing enzymes [176,177] have strong potential as synthetic lethality targets which is currently being explored by our and others' laboratories.

Conclusion and future perspectives

BER/SSBR, the predominant mode of repair for most oxidative genome damage (except DSBs) are critical in preventing mutations and maintaining genomic integrity. Considering the continuous generation of ROS in an aerobic cell due to respiration, and the abundance of oxidative insults inflicted on the genome, it is not surprising that BER/SSBR capacity broadly correlates with an organism's overall life span [178]. As most oxidative bases in the replication fork template fail to block replicative DNA synthesis, these lesions if remain unrepaired would often cause base mutations in the progeny strand. We believe that the 'cow-catcher' role of NEIL1 at replication fork is critical for preventing mutations in dividing cells. Thus BER/SSBR initiating DNA glycosylases not only repair the base damage, but are also involved in damage recognition and pathway choice, the two under-studied aspects.

Another feature of BER/SSBR in higher eukaryotes is their collaboration with components of other cellular pathways which presumably allows tight regulation of the sub-pathways, and also for pathway choice. While many such non-canonical proteins have been shown in *in vitro* and *in-cell* studies to associate with BER/SSBR proteins and stimulate their function, their *in vivo* significance is still obscure. It is possible that these additional factors are utilized for specific repair events/conditions.

Other critical questions that need to be addressed include oxidized lesion scanning in chromatinized genome, repair in hetero versus euchromatin, and involvement of other accessory/non-canonical proteins, particularly factors involved in chromatin unfolding/remodeling in endogenous versus induced damage repair.

Acknowledgments

The authors' research is supported by US Public Health Services Research grants R01 CA158910 (SM), R01 GM105090 (SM), P01 CA92584 (SM), and Muscular Dystrophy Association (MDA 294842; MLH) and ALS Association (ALSA 15-IIP-204; MLH).

References

1. Martinez MC, Andriantsitohaina R. Reactive nitrogen species: molecular mechanisms and potential significance in health and disease. *Antioxid Redox Signal*. 2009; 11 (3):669–702. [PubMed: 19014277]
2. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. *Biochem J*. 1996; 313 (Pt 1):17–29. [PubMed: 8546679]
3. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. *Pharmacol Rev*. 2011; 63 (1):218–242. [PubMed: 21228261]
4. Hegde ML, Hegde PM, Rao KS, Mitra S. Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword. *J Alzheimers Dis*. 2011; 24(Suppl 2):183–198. [PubMed: 21441656]
5. Dizdaroglu M. Oxidatively induced DNA damage: mechanisms, repair and disease. *Cancer Lett*. 2012; 327 (1–2):26–47. [PubMed: 22293091]
6. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. *Cell Res*. 2008; 18 (1):27–47. [PubMed: 18166975]
7. Jones LE Jr, Ying L, Hofseth AB, Jelezcova E, Sobol RW, Ambs S, Harris CC, Espey MG, Hofseth LJ, Wyatt MD. Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. *Carcinogenesis*. 2009; 30 (12):2123–2129. [PubMed: 19864471]
8. Lindahl T. Instability and decay of the primary structure of DNA. *Nature*. 1993; 362 (6422):709–715. [PubMed: 8469282]
9. Thivyanathan V, Somasunderam A, Volk DE, Hazra TK, Mitra S, Gorenstein DG. Base-pairing properties of the oxidized cytosine derivative, 5-hydroxy uracil. *Biochem Biophys Res Commun*. 2008; 366 (3):752–757. [PubMed: 18078807]
10. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. *Nature*. 1991; 349 (6308):431–434. [PubMed: 1992344]
11. Yang N, Galick H, Wallace SS. Attempted base excision repair of ionizing radiation damage in human lymphoblastoid cells produces lethal and mutagenic double strand breaks. *DNA Repair (Amst)*. 2004; 3 (10):1323–1334. [PubMed: 15336627]
12. Odell ID, Wallace SS, Pederson DS. Rules of engagement for base excision repair in chromatin. *J Cell Physiol*. 2013; 228 (2):258–266. [PubMed: 22718094]
13. Lindahl T. An N-glycosidase from *Escherichia coli* that releases free uracil from DNA containing deaminated cytosine residues. *Proc Natl Acad Sci U S A*. 1974; 71 (9):3649–3653. [PubMed: 4610583]
14. Hadi SM, Goldthwait DA. Endonuclease II of *Escherichia coli*. Degradation of partially depurinated deoxyribonucleic acid. *Biochemistry*. 1971; 10 (26):4986–4993. [PubMed: 4944066]
15. Paquette Y, Crine P, Verly WG. Properties of the endonuclease for depurinated DNA from *Escherichia coli*. *Can J Biochem*. 1972; 50 (11):1199–1209. [PubMed: 4565246]
16. Verly WG, Paquette Y. An endonuclease for depurinated DNA in *Escherichia coli* B. *Can J Biochem*. 1972; 50 (2):217–224. [PubMed: 4552312]
17. Laval J. Two enzymes are required from strand incision in repair of alkylated DNA. *Nature*. 1977; 269 (5631):829–832. [PubMed: 927511]
18. Demple B, Herman T, Chen DS. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. *Proc Natl Acad Sci U S A*. 1991; 88 (24):11450–11454. [PubMed: 1722334]

19. Kane CM, Linn S. Purification and characterization of an apurinic/apyrimidinic endonuclease from HeLa cells. *J Biol Chem.* 1981; 256 (7):3405–3414. [PubMed: 6259165]
20. Boiteux S, O'Connor TR, Laval J. Formamidopyrimidine-DNA glycosylase of *Escherichia coli*: cloning and sequencing of the fpg structural gene and overproduction of the protein. *EMBO J.* 1987; 6 (10):3177–3183. [PubMed: 3319582]
21. Jilani A, Ramotar D, Slack C, Ong C, Yang XM, Scherer SW, Lasko DD. Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3'-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage. *J Biol Chem.* 1999; 274 (34):24176–24186. [PubMed: 10446192]
22. Frosina G, Fortini P, Rossi O, Carrozzino F, Raspaglio G, Cox LS, Lane DP, Abbondandolo A, Dogliotti E. Two pathways for base excision repair in mammalian cells. *J Biol Chem.* 1996; 271 (16):9573–9578. [PubMed: 8621631]
23. Fortini P, Pascucci B, Parlanti E, Sobol RW, Wilson SH, Dogliotti E. Different DNA polymerases are involved in the short- and long-patch base excision repair in mammalian cells. *Biochemistry.* 1998; 37 (11):3575–3580. [PubMed: 9530283]
24. Klungland A, Lindahl T. Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). *EMBO J.* 1997; 16 (11):3341–3348. [PubMed: 9214649]
25. Balakrishnan L, Brandt PD, Lindsey-Boltz LA, Sancar A, Bambara RA. Long patch base excision repair proceeds via coordinated stimulation of the multienzyme DNA repair complex. *J Biol Chem.* 2009; 284 (22):15158–15172. [PubMed: 19329425]
26. Petermann E, Ziegler M, Oei SL. ATP-dependent selection between single nucleotide and long patch base excision repair. *DNA Repair (Amst).* 2003; 2 (10):1101–1114. [PubMed: 13679148]
27. Cowell IG, Sunter NJ, Singh PB, Austin CA, Durkacz BW, Tilby MJ. gammaH2AX foci form preferentially in euchromatin after ionising-radiation. *PLoS One.* 2007; 2 (10):e1057. [PubMed: 17957241]
28. Takata H, Hanafusa T, Mori T, Shimura M, Iida Y, Ishikawa K, Yoshikawa K, Yoshikawa Y, Maeshima K. Chromatin compaction protects genomic DNA from radiation damage. *PLoS One.* 2013; 8 (10):e75622. [PubMed: 24130727]
29. Banerjee D, Mandal SM, Das A, Hegde ML, Das S, Bhakat KK, Boldogh I, Sarkar PS, Mitra S, Hazra TK. Preferential repair of oxidized base damage in the transcribed genes of mammalian cells. *J Biol Chem.* 2011; 286 (8):6006–6016. [PubMed: 21169365]
30. Parlanti E, Locatelli G, Maga G, Dogliotti E. Human base excision repair complex is physically associated to DNA replication and cell cycle regulatory proteins. *Nucleic Acids Res.* 2007; 35 (5): 1569–1577. [PubMed: 17289756]
31. Hegde ML, Hegde PM, Bellot LJ, Mandal SM, Hazra TK, Li GM, Boldogh I, Tomkinson AE, Mitra S. Prereplicative repair of oxidized bases in the human genome is mediated by NEIL1 DNA glycosylase together with replication proteins. *Proc Natl Acad Sci U S A.* 2013; 110 (33):E3090–3099. [PubMed: 23898192]
32. Dou H, Mitra S, Hazra TK. Repair of oxidized bases in DNA bubble structures by human DNA glycosylases NEIL1 and NEIL2. *J Biol Chem.* 2003; 278 (50):49679–49684. [PubMed: 14522990]
33. Dou H, Theriot CA, Das A, Hegde ML, Matsumoto Y, Boldogh I, Hazra TK, Bhakat KK, Mitra S. Interaction of the human DNA glycosylase NEIL1 with proliferating cell nuclear antigen. The potential for replication-associated repair of oxidized bases in mammalian genomes. *J Biol Chem.* 2008; 283 (6):3130–3140. [PubMed: 18032376]
34. Otterlei M, Warbrick E, Nagelhus TA, Haug T, Slupphaug G, Akbari M, Aas PA, Steinsbekk K, Bakke O, Krokan HE. Post-replicative base excision repair in replication foci. *EMBO J.* 1999; 18 (13):3834–3844. [PubMed: 10393198]
35. Hayashi H, Tominaga Y, Hirano S, McKenna AE, Nakabeppu Y, Matsumoto Y. Replication-associated repair of adenine:8-oxoguanine mispairs by MYH. *Curr Biol.* 2002; 12 (4):335–339. [PubMed: 11864576]
36. Rao S, Chenna A, Slupska M, Singer B. Replication of O4-methylthymine-containing oligonucleotides: effect of 3' and 5' flanking bases on formation and extension of O4-methylthymine. guanine basepairs. *Mutat Res.* 1996; 356 (2):179–185. [PubMed: 8841483]

37. Le Page F, Guy A, Cadet J, Sarasin A, Gentil A. Repair and mutagenic potency of 8-oxoG:A and 8-oxoG:C base pairs in mammalian cells. *Nucleic Acids Res.* 1998; 26 (5):1276–1281. [PubMed: 9469837]
38. Boldogh I, Milligan D, Lee MS, Bassett H, Lloyd RS, McCullough AK. hMYH cell cycle-dependent expression, subcellular localization and association with replication foci: evidence suggesting replication-coupled repair of adenine:8-oxoguanine mispairs. *Nucleic Acids Res.* 2001; 29 (13):2802–2809. [PubMed: 11433026]
39. Theriot CA, Hegde ML, Hazra TK, Mitra S. RPA physically interacts with the human DNA glycosylase NEIL1 to regulate excision of oxidative DNA base damage in primer-template structures. *DNA Repair (Amst).* 2010; 9 (6):643–652. [PubMed: 20338831]
40. Bansbach CE, Betous R, Lovejoy CA, Glick GG, Cortez D. The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks. *Genes & development.* 2009; 23 (20): 2405–2414. [PubMed: 19793861]
41. Betous R, Mason AC, Rambo RP, Bansbach CE, Badu-Nkansah A, Sirbu BM, Eichman BF, Cortez D. SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication. *Genes & development.* 2012; 26 (2):151–162. [PubMed: 22279047]
42. Evans J, Maccabee M, Hatahet Z, Courcelle J, Bockrath R, Ide H, Wallace S. Thymine ring saturation and fragmentation products: lesion bypass, misinsertion and implications for mutagenesis. *Mutat Res.* 1993; 299 (3–4):147–156. [PubMed: 7683083]
43. Tornaletti S, Maeda LS, Lloyd DR, Reines D, Hanawalt PC. Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II. *J Biol Chem.* 2001; 276 (48):45367–45371. [PubMed: 11571287]
44. Zhao X, Krishnamurthy N, Burrows CJ, David SS. Mutation versus repair: NEIL1 removal of hydantoin lesions in single-stranded, bulge, bubble, and duplex DNA contexts. *Biochemistry.* 2011; 49 (8):1658–1666. [PubMed: 20099873]
45. Banerjee D, Mandal SM, Das A, Hegde ML, Das S, Bhakat KK, Boldogh I, Sarkar PS, Mitra S, Hazra TK. Preferential repair of oxidized base damage in the transcribed genes of mammalian cells. *J Biol Chem.* 2011 In Press.
46. Takao M, Kanno S, Kobayashi K, Zhang QM, Yonei S, van der Horst GT, Yasui A. A back-up glycosylase in Nth1 knock-out mice is a functional Nei (endonuclease VIII) homologue. *J Biol Chem.* 2002; 277 (44):42205–42213. [PubMed: 12200441]
47. Mitra, S.; Hegde, ML.; Theriot, CA.; Das, A.; Hegde, PM.; Hazra, TK. Complexity in repair of oxidative genome damage and its regulation. *Proceedings of Princess Takamatsu Symposium*; Tokyo, Japan. 2009.
48. Kavli B, Sundheim O, Akbari M, Otterlei M, Nilsen H, Skorpen F, Aas PA, Hagen L, Krokan HE, Slupphaug G. hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. *J Biol Chem.* 2002; 277 (42):39926–39936. [PubMed: 12161446]
49. Vartanian V, Lowell B, Minko IG, Wood TG, Ceci JD, George S, Ballinger SW, Corless CL, McCullough AK, Lloyd RS. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. *Proc Natl Acad Sci U S A.* 2006; 103 (6):1864–1869. [PubMed: 16446448]
50. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, Seeberg E, Lindahl T, Barnes DE. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. *Proc Natl Acad Sci U S A.* 1999; 96 (23):13300–13305. [PubMed: 10557315]
51. Minowa O, Arai H, Hirano M, Monden Y, Nakai S, Fukuda M, Itoh M, Takano H, Hippou Y, Aburatani H, Masumura K, Nohmi T, Nishimura S, Noda T. Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. *Proc Natl Acad Sci U S A.* 2000; 97 (8):4156–4161. [PubMed: 10725358]
52. Chan MK, Ocampo-Hafalla MT, Vartanian V, Jaruga P, Kirkali G, Koenig KL, Brown S, Lloyd RS, Dizdaroglu M, Teebor GW. Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA. *DNA Repair (Amst).* 2009; 8 (7):786–794. [PubMed: 19346169]

53. Xie Y, Yang H, Cunanan C, Okamoto K, Shibata D, Pan J, Barnes DE, Lindahl T, McIlhatton M, Fishel R, Miller JH. Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors. *Cancer Res.* 2004; 64 (9):3096–3102. [PubMed: 15126346]
54. Russo MT, De Luca G, Degan P, Parlanti E, Dogliotti E, Barnes DE, Lindahl T, Yang H, Miller JH, Bignami M. Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the Myh and Ogg1 DNA glycosylases. *Cancer Res.* 2004; 64 (13): 4411–4414. [PubMed: 15231648]
55. Parrilla-Castellar ER, Arlander SJ, Karnitz L. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. *DNA Repair (Amst).* 2004; 3 (8–9):1009–1014. [PubMed: 15279787]
56. Pichierri P, Nicolai S, Cignolo L, Bignami M, Franchitto A. The RAD9-RAD1-HUS1 (9.1.1) complex interacts with WRN and is crucial to regulate its response to replication fork stalling. *Oncogene.* 2012; 31 (23):2809–2823. [PubMed: 22002307]
57. Machwe A, Xiao L, Lloyd RG, Bolt E, Orren DK. Replication fork regression in vitro by the Werner syndrome protein (WRN): holliday junction formation, the effect of leading arm structure and a potential role for WRN exonuclease activity. *Nucleic Acids Res.* 2007; 35 (17):5729–5747. [PubMed: 17717003]
58. Guan X, Bai H, Shi G, Theriot CA, Hazra TK, Mitra S, Lu AL. The human checkpoint sensor Rad9-Rad1-Hus1 interacts with and stimulates NEIL1 glycosylase. *Nucleic Acids Res.* 2007; 35 (8):2463–2472. [PubMed: 17395641]
59. Guan X, Madabushi A, Chang DY, Fitzgerald ME, Shi G, Drohat AC, Lu AL. The human checkpoint sensor Rad9-Rad1-Hus1 interacts with and stimulates DNA repair enzyme TDG glycosylase. *Nucleic Acids Res.* 2007; 35 (18):6207–6218. [PubMed: 17855402]
60. Touille M, El-Andaloussi N, Frouin I, Freire R, Funk D, Shevelev I, Friedrich-Heineken E, Villani G, Hottiger MO, Hubscher U. The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA polymerase beta and increases its DNA substrate utilisation efficiency: implications for DNA repair. *Nucleic Acids Res.* 2004; 32 (11):3316–3324. [PubMed: 15314187]
61. Smirnova E, Touille M, Markkanen E, Hubscher U. The human checkpoint sensor and alternative DNA clamp Rad9-Rad1-Hus1 modulates the activity of DNA ligase I, a component of the long-patch base excision repair machinery. *Biochem J.* 2005; 389 (Pt 1):13–17. [PubMed: 15871698]
62. Wang W, Brandt P, Rossi ML, Lindsey-Boltz L, Podust V, Fanning E, Sancar A, Bambara RA. The human Rad9-Rad1-Hus1 checkpoint complex stimulates flap endonuclease 1. *Proc Natl Acad Sci U S A.* 2004; 101 (48):16762–16767. [PubMed: 15556996]
63. Fan J, Wilson DM 3rd. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. *Free Radic Biol Med.* 2005; 38 (9):1121–1138. [PubMed: 15808410]
64. Xia K, Fu Z, Hou L, Han JD. Impacts of protein-protein interaction domains on organism and network complexity. *Genome Res.* 2008; 18 (9):1500–1508. [PubMed: 18687879]
65. Liu X, Roy R. Truncation of amino-terminal tail stimulates activity of human endonuclease III (hNTH1). *J Mol Biol.* 2002; 321 (2):265–276. [PubMed: 12144783]
66. Doublet S, Bandaru V, Bond JP, Wallace SS. The crystal structure of human endonuclease VIII-like 1 (NEIL1) reveals a zincless finger motif required for glycosylase activity. *Proc Natl Acad Sci U S A.* 2004; 101 (28):10284–10289. [PubMed: 15232006]
67. Wiederhold L, Leppard JB, Kedar P, Karimi-Busheri F, Rasouli-Nia A, Weinfeld M, Tomkinson AE, Izumi T, Prasad R, Wilson SH, Mitra S, Hazra TK. AP endonuclease-independent DNA base excision repair in human cells. *Mol Cell.* 2004; 15 (2):209–220. [PubMed: 15260972]
68. Hegde ML, Hegde PM, Arijit D, Boldogh I, Mitra S. Human DNA Glycosylase NEIL1's Interactions with Downstream Repair Proteins Is Critical for Efficient Repair of Oxidized DNA Base Damage and Enhanced Cell Survival. *Biomolecules.* 2012; 2 (4):564–578. [PubMed: 23926464]
69. Hegde ML, Tsutakawa SE, Hegde PM, Holthauzen LM, Li J, Oezguen N, Hilser VJ, Tainer JA, Mitra S. The disordered C-terminal domain of human DNA glycosylase NEIL1 contributes to its stability via intramolecular interactions. *J Mol Biol.* 2013; 425 (13):2359–2371. [PubMed: 23542007]

70. Bhakat KK, Mantha AK, Mitra S. Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. *Antioxid Redox Signal*. 2009; 11 (3):621–638. [PubMed: 18715144]
71. Izumi T, Mitra S. Deletion analysis of human AP-endonuclease: minimum sequence required for the endonuclease activity. *Carcinogenesis*. 1998; 19 (3):525–527. [PubMed: 9525290]
72. Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK, Kohno K, Mitra S, Bhakat KK. Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. *Mol Cell Biol*. 2008; 28 (23):7066–7080. [PubMed: 18809583]
73. Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. *Oncogene*. 2011; 30 (4):482–493. [PubMed: 20856196]
74. Fantini D, Vascotto C, Deganuto M, Bivi N, Gustincich S, Marcon G, Quadrifoglio F, Damante G, Bhakat KK, Mitra S, Tell G. APE1/Ref-1 regulates PTEN expression mediated by Egr-1. *Free Radic Res*. 2008; 42 (1):20–29. [PubMed: 18324520]
75. Sengupta S, Mitra S, Bhakat KK. Dual regulatory roles of human AP-endonuclease (APE1/Ref-1) in CDKN1A/p21 expression. *PLoS One*. 2013; 8 (7):e68467. [PubMed: 23874636]
76. Popuri V, Croteau DL, Bohr VA. Substrate specific stimulation of NEIL1 by WRN but not the other human RecQ helicases. *DNA Repair (Amst)*. 2010; 9 (6):636–642. [PubMed: 20346739]
77. Hegde ML, Banerjee S, Hegde PM, Bellot LJ, Hazra TK, Boldogh I, Mitra S. Enhancement of NEIL1 protein-initiated oxidized DNA base excision repair by heterogeneous nuclear ribonucleoprotein U (hnRNP-U) via direct interaction. *J Biol Chem*. 2012; 287 (41):34202–34211. [PubMed: 22902625]
78. Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. *Cell Mol Life Sci*. 2010; 67 (21):3573–3587. [PubMed: 20714778]
79. Hsu WL, Oldfield C, Meng J, Huang F, Xue B, Uversky VN, Romero P, Dunker AK. Intrinsic protein disorder and protein-protein interactions. *Pac Symp Biocomput*. 2012; 116–127. [PubMed: 22174268]
80. Hanssen-Bauer A, Solvang-Garten K, Sundheim O, Pena-Diaz J, Andersen S, Slupphaug G, Krokan HE, Wilson DM 3rd, Akbari M, Otterlei M. XRCC1 coordinates disparate responses and multiprotein repair complexes depending on the nature and context of the DNA damage. *Environ Mol Mutagen*. 2011; 52 (8):623–635. [PubMed: 21786338]
81. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. *Nucleic Acids Res*. 1995; 23 (23):4836–4843. [PubMed: 8532526]
82. Fan J, Otterlei M, Wong HK, Tomkinson AE, Wilson DM 3rd. XRCC1 co-localizes and physically interacts with PCNA. *Nucleic Acids Res*. 2004; 32 (7):2193–2201. [PubMed: 15107487]
83. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. *EMBO J*. 2001; 20 (22):6530–6539. [PubMed: 11707423]
84. Marsin S, Vidal AE, Sossou M, Menissier-de Murcia J, Le Page F, Boiteux S, de Murcia G, Radicella JP. Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. *J Biol Chem*. 2003; 278 (45):44068–44074. [PubMed: 12933815]
85. Della-Maria J, Hegde ML, McNeill DR, Matsumoto Y, Tsai MS, Ellenberger T, Wilson DM 3rd, Mitra S, Tomkinson AE. The interaction between polynucleotide kinase phosphatase and the DNA repair protein XRCC1 is critical for repair of DNA alkylation damage and stable association at DNA damage sites. *J Biol Chem*. 2012; 287 (46):39233–39244. [PubMed: 22992732]
86. Campalans A, Marsin S, Nakabeppu Y, O'Connor TR, Boiteux S, Radicella JP. XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. *DNA Repair (Amst)*. 2005; 4 (7):826–835. [PubMed: 15927541]
87. Gary R, Kim K, Cornelius HL, Park MS, Matsumoto Y. Proliferating cell nuclear antigen facilitates excision in long-patch base excision repair. *J Biol Chem*. 1999; 274 (7):4354–4363. [PubMed: 9933638]

88. Gabel SA, DeRose EF, London RE. XRCC1 interaction with the REV1 C-terminal domain suggests a role in post replication repair. *DNA Repair (Amst)*. 2013; 12 (12):1105–1113. [PubMed: 24409475]
89. Ogi T, Limsirichaikul S, Overmeer RM, Volker M, Takenaka K, Cloney R, Nakazawa Y, Niimi A, Miki Y, Jaspers NG, Mullenders LH, Yamashita S, Foustier MI, Lehmann AR. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. *Mol Cell*. 2010; 37 (5):714–727. [PubMed: 20227374]
90. Chou WC, Wang HC, Wong FH, Ding SL, Wu PE, Shieh SY, Shen CY. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. *EMBO J*. 2008; 27 (23):3140–3150. [PubMed: 18971944]
91. Marintchev A, Mullen MA, Maciejewski MW, Pan B, Gryk MR, Mullen GP. Solution structure of the single-strand break repair protein XRCC1 N-terminal domain. *Nat Struct Biol*. 1999; 6 (9): 884–893. [PubMed: 10467102]
92. Marintchev A, Robertson A, Dimitriadis EK, Prasad R, Wilson SH, Mullen GP. Domain specific interaction in the XRCC1-DNA polymerase beta complex. *Nucleic Acids Res*. 2000; 28 (10): 2049–2059. [PubMed: 10773072]
93. Marintchev A, Gryk MR, Mullen GP. Site-directed mutagenesis analysis of the structural interaction of the single-strand-break repair protein, X-ray cross-complementing group 1, with DNA polymerase beta. *Nucleic Acids Res*. 2003; 31 (2):580–588. [PubMed: 12527765]
94. Caldecott KW. XRCC1 and DNA strand break repair. *DNA Repair (Amst)*. 2003; 2 (9):955–969. [PubMed: 12967653]
95. Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, Prasad R, Kedar PS, Derose EF, Hou EW, London RE, Wilson SH. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. *DNA Repair (Amst)*. 2013; 12 (9):774–785. [PubMed: 23871146]
96. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD⁺ into a nuclear signal. *Genes Dev*. 2005; 19 (17):1951–1967. [PubMed: 16140981]
97. Ame JC, Spencehauer C, de Murcia G. The PARP superfamily. *Bioessays*. 2004; 26 (8):882–893. [PubMed: 15273990]
98. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, Poirier GG, Dawson VL, Dawson TM. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). *Sci Signal*. 2011; 4(167):ra20. [PubMed: 21467298]
99. Kraus WL, Lis JT. PARP goes transcription. *Cell*. 2003; 113 (6):677–683. [PubMed: 12809599]
100. Langelier MF, Servent KM, Rogers EE, Pascal JM. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. *J Biol Chem*. 2008; 283 (7):4105–4114. [PubMed: 18055453]
101. Langelier MF, Ruhl DD, Planck JL, Kraus WL, Pascal JM. The Zn³ domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. *J Biol Chem*. 2010; 285 (24):18877–18887. [PubMed: 20388712]
102. Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL. NAD⁺-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. *Cell*. 2004; 119 (6): 803–814. [PubMed: 15607977]
103. Ali AA, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, Ladurner AG, Pearl LH, Oliver AW. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. *Nat Struct Mol Biol*. 2012; 19 (7):685–692. [PubMed: 22683995]
104. Davidovic L, Vodenicharov M, Affar EB, Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. *Exp Cell Res*. 2001; 268 (1):7–13. [PubMed: 11461113]
105. Beernink PT, Hwang M, Ramirez M, Murphy MB, Doyle SA, Thelen MP. Specificity of protein interactions mediated by BRCT domains of the XRCC1 DNA repair protein. *J Biol Chem*. 2005; 280 (34):30206–30213. [PubMed: 15987676]

106. Wei L, Nakajima S, Hsieh CL, Kanno S, Masutani M, Levine AS, Yasui A, Lan L. Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose). *J Cell Sci.* 2013; 126 (Pt 19):4414–4423. [PubMed: 23868975]
107. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. *Nucleic Acids Res.* 2006; 34 (21):6170–6182. [PubMed: 17088286]
108. Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. *Nucleic Acids Res.* 2010; 38 (18):6065–6077. [PubMed: 20483915]
109. Robert I, Dantzer F, Reina-San-Martin B. Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. *J Exp Med.* 2009; 206 (5):1047–1056. [PubMed: 19364882]
110. Noren Hooten N, Fitzpatrick M, Kompaniez K, Jacob KD, Moore BR, Nagle J, Barnes J, Lohani A, Evans MK. Coordination of DNA repair by NEIL1 and PARP-1: a possible link to aging. *Aging (Albany NY).* 2012; 4 (10):674–685. [PubMed: 23104860]
111. Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, Zhao GY, Saberi A, Masutani M, Adachi N, Koyama H, de Murcia G, Takeda S. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. *EMBO J.* 2006; 25 (6):1305–1314. [PubMed: 16498404]
112. Mansour WY, Borgmann K, Petersen C, Dikomey E, Dahm-Daphi J. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining. *DNA Repair (Amst).* 2013; 12 (12):1134–1142. [PubMed: 24210699]
113. Haince JF, McDonald D, Rodrigue A, Dery U, Masson JY, Hendzel MJ, Poirier GG. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. *J Biol Chem.* 2008; 283 (2):1197–1208. [PubMed: 18025084]
114. Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. *J Cell Biol.* 2008; 183 (7):1203–1212. [PubMed: 19103807]
115. Ying S, Hamdy FC, Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. *Cancer Res.* 2012; 72 (11):2814–2821. [PubMed: 22447567]
116. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. *Mol Aspects Med.* 2013; 34 (6):1217–1256. [PubMed: 23370117]
117. Telli ML, Ford JM. PARP inhibitors in breast cancer. *Clin Adv Hematol Oncol.* 2010; 8 (9):629–635. [PubMed: 21157412]
118. Fathers C, Drayton RM, Solovieva S, Bryant HE. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. *Cell Cycle.* 2012; 11 (5):990–997. [PubMed: 22333589]
119. Berghammer H, Ebner M, Marksteiner R, Auer B. pADPRT-2: a novel mammalian polymerizing(ADP-ribosyl)transferase gene related to truncated pADPRT homologues in plants and *Caenorhabditis elegans*. *FEBS Lett.* 1999; 449 (2–3):259–263. [PubMed: 10338144]
120. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosylation) by PARP-1 is required for rapid response to DNA damage in living cells. *Nucleic Acids Res.* 2007; 35 (22):7665–7675. [PubMed: 17982172]
121. Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3. *Exp Cell Res.* 2014; 329 (1): 18–25. [PubMed: 25017100]
122. Beck C, Boehler C, Guirouilh Barbat J, Bonnet ME, Illuzzi G, Ronde P, Gauthier LR, Magroun N, Rajendran A, Lopez BS, Scully R, Boussin FD, Schreiber V, Dantzer F. PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. *Nucleic Acids Res.* 2014; 42 (9):5616–5632. [PubMed: 24598253]

123. Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L, Poirier G, Reina-San-Martin B, Caldecott KW. PARP-3 and APLF function together to accelerate nonhomologous end-joining. *Mol Cell*. 2011; 41 (1):33–45. [PubMed: 21211721]
124. Han SP, Tang YH, Smith R. Functional diversity of the hnRNPs: past, present and perspectives. *Biochem J*. 2010; 430 (3):379–392. [PubMed: 20795951]
125. Hasegawa Y, Brockdorff N, Kawano S, Tsutui K, Tsutui K, Nakagawa S. The matrix protein hnRNP U is required for chromosomal localization of Xist RNA. *Dev Cell*. 2010; 19 (3):469–476. [PubMed: 20833368]
126. Haley B, Paunesku T, Protic M, Woloschak GE. Response of heterogeneous ribonuclear proteins (hnRNP) to ionising radiation and their involvement in DNA damage repair. *Int J Radiat Biol*. 2009; 85 (8):643–655. [PubMed: 19579069]
127. Berglund FM, Clarke PR. hnRNP-U is a specific DNA-dependent protein kinase substrate phosphorylated in response to DNA double-strand breaks. *Biochem Biophys Res Commun*. 2009; 381 (1):59–64. [PubMed: 19351595]
128. Mandal SM, Hegde ML, Chatterjee A, Hegde PM, Szczesny B, Banerjee D, Boldogh I, Gao R, Falkenberg M, Gustafsson CM, Sarkar PS, Hazra TK. Role of human DNA glycosylase Nei-like 2 (NEIL2) and single strand break repair protein polynucleotide kinase 3'-phosphatase in maintenance of mitochondrial genome. *J Biol Chem*. 2012; 287 (4):2819–2829. [PubMed: 22130663]
129. Britton S, Froment C, Frit P, Monsarrat B, Salles B, Calsou P. Cell nonhomologous end joining capacity controls SAF-A phosphorylation by DNA-PK in response to DNA double-strand breaks inducers. *Cell Cycle*. 2009; 8 (22):3717–3722. [PubMed: 19844162]
130. Polo SE, Blackford AN, Chapman JR, Baskcomb L, Gravel S, Rusch A, Thomas A, Blundred R, Smith P, Kzhyshkowska J, Dobner T, Taylor AM, Turnell AS, Stewart GS, Grand RJ, Jackson SP. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. *Mol Cell*. 2012; 45 (4):505–516. [PubMed: 22365830]
131. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. *Biochemistry (Mosc)*. 2011; 76 (13):1402–1433. [PubMed: 22339596]
132. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, Uchiumi T, Kuwano M, Kohno K. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. *Cancer Res*. 1999; 59 (2):342–346. [PubMed: 9927044]
133. Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. *Nucleic Acids Res*. 2004; 32 (1):316–327. [PubMed: 14718551]
134. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, Wilson SH, Hazra TK. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. *J Biol Chem*. 2007; 282 (39):28474–28484. [PubMed: 17686777]
135. Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB-1 protein: functions and regulation. *Wiley Interdiscip Rev RNA*. 2014; 5 (1):95–110. [PubMed: 24217978]
136. Marenstein DR, Ocampo MT, Chan MK, Altamirano A, Basu AK, Boorstein RJ, Cunningham RP, Teebor GW. Stimulation of human endonuclease III by Y box-binding protein 1 (DNA-binding protein B). Interaction between a base excision repair enzyme and a transcription factor. *J Biol Chem*. 2001; 276 (24):21242–21249. [PubMed: 11287425]
137. Pestryakov P, Zharkov DO, Grin I, Fomina EE, Kim ER, Hamon L, Eliseeva IA, Petrusheva IO, Curmi PA, Ovchinnikov LP, Lavrik OI. Effect of the multifunctional proteins RPA, YB-1, and XPC repair factor on AP site cleavage by DNA glycosylase NEIL1. *J Mol Recognit*. 2012; 25 (4):224–233. [PubMed: 22434712]
138. Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, Robinson PJ, Braithwaite AW. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. *Oncogene*. 2010; 29 (3):403–410. [PubMed: 19838214]
139. Liu Y, Prasad R, Wilson SH. HMGB1: roles in base excision repair and related function. *Biochim Biophys Acta*. 2010; 1799 (1–2):119–130. [PubMed: 20123074]

140. Lange SS, Reddy MC, Vasquez KM. Human HMGB1 directly facilitates interactions between nucleotide excision repair proteins on triplex-directed psoralen interstrand crosslinks. *DNA Repair (Amst)*. 2009; 8 (7):865–872. [PubMed: 19446504]
141. Lange SS, Vasquez KM. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. *Mol Carcinog*. 2009; 48 (7):571–580. [PubMed: 19360789]
142. Prasad R, Liu Y, Deterding LJ, Poltoratsky VP, Kedar PS, Horton JK, Kanno S, Asagoshi K, Hou EW, Khodyreva SN, Lavrik OI, Tomer KB, Yasui A, Wilson SH. HMGB1 is a cofactor in mammalian base excision repair. *Mol Cell*. 2007; 27 (5):829–841. [PubMed: 17803946]
143. Bonaldi T, Langst G, Strohn R, Becker PB, Bianchi ME. The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. *EMBO J*. 2002; 21 (24):6865–6873. [PubMed: 12486007]
144. Lange SS, Mitchell DL, Vasquez KM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. *Proc Natl Acad Sci U S A*. 2008; 105 (30):10320–10325. [PubMed: 18650382]
145. Belgrano FS, de Abreu da Silva IC, Bastos de Oliveira FM, Fantappie MR, Mohana-Borges R. Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending. *PLoS One*. 2013; 8 (11):e79572. [PubMed: 24255708]
146. Ugrinova I, Zlateva S, Pashev IG, Pasheva EA. Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. *Int J Biochem Cell Biol*. 2009; 41 (7):1556–1562. [PubMed: 19401149]
147. Topalova D, Ugrinova I, Pashev IG, Pasheva EA. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. *Int J Biochem Cell Biol*. 2008; 40 (8):1536–1542. [PubMed: 18191612]
148. Jeppesen DK, Bohr VA, Stevnsner T. DNA repair deficiency in neurodegeneration. *Prog Neurobiol*. 2011; 94 (2):166–200. [PubMed: 21550379]
149. Cheng CX, Xue M, Li K, Li WS. Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. *Asian Pac J Cancer Prev*. 2012; 13 (6):2541–2545. [PubMed: 22938418]
150. Chiyomaru K, Nagano T, Nishigori C. XRCC1 Arg194Trp polymorphism, risk of nonmelanoma skin cancer and extramammary Paget's disease in a Japanese population. *Arch Dermatol Res*. 2012; 304 (5):363–370. [PubMed: 22639094]
151. Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Perez M, Peregrina-Sandoval J, Leal-Ugarte E, Macias-Gomez N, Peralta-Leal V, Meza-Espinoza JP, Moreno-Ortiz JM, Ramirez-Ramirez R, Suarez-Villanueva S, Gutierrez-Angulo M. MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. *Genet Mol Res*. 2012; 11 (3):2315–2320. [PubMed: 22843073]
152. Nakao M, Hosono S, Ito H, Watanabe M, Mizuno N, Sato S, Yatabe Y, Yamao K, Ueda R, Tajima K, Tanaka H, Matsuo K. Selected polymorphisms of base excision repair genes and pancreatic cancer risk in Japanese. *J Epidemiol*. 2012; 22 (6):477–483. [PubMed: 22850545]
153. Wang N, Wu YJ, Zhou XL, Wu YM. The polymorphisms of XRCC1 gene and susceptibility to pulmonary cancer. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi*. 2012; 30 (1):41–44. [PubMed: 22730687]
154. Zhi Y, Yu J, Liu Y, Wei Q, Yuan F, Zhou X, Song B, Chen Z, Yang J. Interaction between polymorphisms of DNA repair genes significantly modulated bladder cancer risk. *Int J Med Sci*. 2012; 9 (6):498–505. [PubMed: 22927776]
155. Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse C, Chan S, Madhusudan S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. *PLoS One*. 2013; 8 (2):e57098. [PubMed: 23451157]
156. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C, Ball G, Chan S, Rakha EA, Ellis IO, Madhusudan S. Targeting XRCC1 deficiency in breast cancer for personalized therapy. *Cancer Res*. 2013; 73 (5):1621–1634. [PubMed: 23253910]
157. Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, Madhusudan S. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. *Int J Cancer*. 2013; 132 (12):2778–2786. [PubMed: 23225521]

158. Chen B, Zhou Y, Yang P, Wu XT. Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis. *Mol Biol Rep.* 2012; 39 (2):1305–1313. [PubMed: 21604176]
159. Tebbs RS, Flannery ML, Meneses JJ, Hartmann A, Tucker JD, Thompson LH, Cleaver JE, Pedersen RA. Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. *Dev Biol.* 1999; 208 (2):513–529. [PubMed: 10191063]
160. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. *Oncogene.* 2006; 25 (11):1612–1619. [PubMed: 16550161]
161. Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. *Gastroenterology.* 2005; 128 (7):1919–1936. [PubMed: 15940627]
162. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. *Cancer Res.* 1990; 50 (1):38–43. [PubMed: 2104538]
163. Noshio K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, Imamura A, Imai K, Shinomura Y. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. *Eur J Cancer.* 2006; 42 (14):2374–2381. [PubMed: 16809031]
164. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. *Am J Hematol.* 1991; 37 (4):223–227. [PubMed: 1907096]
165. Ghabreau L, Roux JP, Frappart PO, Mathevet P, Patricot LM, Mokni M, Korbi S, Wang ZQ, Tong WM, Frappart L. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. *Int J Cancer.* 2004; 109 (3):317–321. [PubMed: 14961567]
166. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. *Genes Cancer.* 2010; 1 (8):812–821. [PubMed: 21779467]
167. Quiles-Perez R, Munoz-Gamez JA, Ruiz-Extremera A, O'Valle F, Sanjuan-Nunez L, Martin-Alvarez AB, Martin-Oliva D, Caballero T, Munoz de Rueda P, Leon J, Gonzalez R, Muntane J, Oliver FJ, Salmeron J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. *Hepatology.* 2010; 51 (1):255–266. [PubMed: 20034026]
168. Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. *Curr Probl Cancer.* 2011; 35 (1):7–50. [PubMed: 21300207]
169. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. *Int J Gynecol Pathol.* 2007; 26 (2):147–153. [PubMed: 17413981]
170. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. *Cancer Discov.* 2012; 2 (9):798–811. [PubMed: 22961666]
171. Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. *Carcinogenesis.* 2013; 34 (4):739–749. [PubMed: 23275151]
172. Wilson DM 3rd, Kim D, Berquist BR, Sigurdson AJ. Variation in base excision repair capacity. *Mutat Res.* 2011; 711 (1–2):100–112. [PubMed: 21167187]
173. Nemec AA, Wallace SS, Sweasy JB. Variant base excision repair proteins: contributors to genomic instability. *Semin Cancer Biol.* 2010; 20 (5):320–328. [PubMed: 20955798]
174. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. *Cell Cycle.* 2011; 10 (8):1192–1199. [PubMed: 21487248]
175. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S. Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential

- etiological linkage to neurodegenerative diseases. *J Biol Chem.* 2010; 285 (37):28812–28825. [PubMed: 20622253]
176. Tomkinson AE, Howes TR, Wiest NE. DNA ligases as therapeutic targets. *Transl Cancer Res.* 2013; 2(3)
 177. Tomkinson AE, Chen L, Dong Z, Leppard JB, Levin DS, Mackey ZB, Motycka TA. Completion of base excision repair by mammalian DNA ligases. *Prog Nucleic Acid Res Mol Biol.* 2001; 68:151–164. [PubMed: 11554294]
 178. Lillenes MS, Espeseth T, Stoen M, Lundervold AJ, Frye SA, Rootwelt H, Reinvang I, Tonjum T. DNA base excision repair gene polymorphisms modulate human cognitive performance and decline during normal life span. *Mech Ageing Dev.* 2011; 132 (8–9):449–458. [PubMed: 21884718]
 179. Liu Y, Prasad R, Beard WA, Hou EW, Horton JK, McMurray CT, Wilson SH. Coordination between polymerase beta and FEN1 can modulate CAG repeat expansion. *J Biol Chem.* 2009; 284 (41):28352–28366. [PubMed: 19674974]
 180. Noren Hooten N, Kompaniez K, Barnes J, Lohani A, Evans MK. Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1). *J Biol Chem.* 2011; 286 (52): 44679–44690. [PubMed: 22057269]
 181. Harris JL, Jakob B, Taucher-Scholz G, Dianov GL, Becherel OJ, Lavin MF. Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage. *Hum Mol Genet.* 2009; 18 (21):4102–4117. [PubMed: 19643912]
 182. Kleppa L, Mari PO, Larsen E, Lien GF, Godon C, Theil AF, Nesse GJ, Wiksen H, Vermeulen W, Giglia-Mari G, Klungland A. Kinetics of endogenous mouse FEN1 in base excision repair. *Nucleic Acids Res.* 2012; 40 (18):9044–9059. [PubMed: 22810208]
 183. Koch CA, Agyei R, Galicia S, Metalnikov P, O'Donnell P, Starostine A, Weinfeld M, Durocher D. Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV. *EMBO J.* 2004; 23 (19):3874–3885. [PubMed: 15385968]
 184. Frouin I, Maga G, Denegri M, Riva F, Savio M, Spadari S, Prosperi E, Scovassi AI. Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1. A dynamic exchange of partners. *J Biol Chem.* 2003; 278 (41):39265–39268. [PubMed: 12930846]
 185. Sukhanova M, Khodyreva S, Lavrik O. Poly(ADP-ribose) polymerase 1 regulates activity of DNA polymerase beta in long patch base excision repair. *Mutat Res.* 2010; 685 (1–2):80–89. [PubMed: 19703477]
 186. Leppard JB, Dong Z, Mackey ZB, Tomkinson AE. Physical and functional interaction between DNA ligase IIIalpha and poly(ADP-Ribose) polymerase 1 in DNA single-strand break repair. *Mol Cell Biol.* 2003; 23 (16):5919–5927. [PubMed: 12897160]
 187. von Kobbe C, Harrigan JA, Schreiber V, Stiegler P, Piotrowski J, Dawut L, Bohr VA. Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein. *Nucleic Acids Res.* 2004; 32 (13):4003–4014. [PubMed: 15292449]
 188. Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. Visualization of a DNA-PK/PARP1 complex. *Nucleic Acids Res.* 2012; 40 (9):4168–4177. [PubMed: 22223246]
 189. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. *Mol Cell Biol.* 1998; 18 (6):3563–3571. [PubMed: 9584196]
 190. Luo H, Chan DW, Yang T, Rodriguez M, Chen BP, Leng M, Mu JJ, Chen D, Songyang Z, Wang Y, Qin J. A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. *Mol Cell Biol.* 2004; 24 (19):8356–8365. [PubMed: 15367657]
 191. Dianova II, Sleeth KM, Allinson SL, Parsons JL, Breslin C, Caldecott KW, Dianov GL. XRCC1-DNA polymerase beta interaction is required for efficient base excision repair. *Nucleic Acids Res.* 2004; 32 (8):2550–2555. [PubMed: 15141024]
 192. Cuneo MJ, London RE. Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase beta binding affinity. *Proc Natl Acad Sci U S A.* 2010; 107 (15):6805–6810. [PubMed: 20351257]

193. Caldecott KW, McKeown CK, Tucker JD, Ljungquist S, Thompson LH. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. *Mol Cell Biol.* 1994; 14 (1):68–76. [PubMed: 8264637]
194. Cuneo MJ, Gabel SA, Krahn JM, Ricker MA, London RE. The structural basis for partitioning of the XRCC1/DNA ligase III-alpha BRCT-mediated dimer complexes. *Nucleic Acids Res.* 2011; 39 (17):7816–7827. [PubMed: 21652643]
195. Mortusewicz O, Leonhardt H. XRCC1 and PCNA are loading platforms with distinct kinetic properties and different capacities to respond to multiple DNA lesions. *BMC Mol Biol.* 2007; 8:81. [PubMed: 17880707]
196. Levy N, Martz A, Bresson A, Spenlehauer C, de Murcia G, Menissier-de Murcia J. XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage. *Nucleic Acids Res.* 2006; 34 (1):32–41. [PubMed: 16397295]
197. Chang YW, Mai RT, Fang WH, Lin CC, Chiu CC, Wu Lee YH. YB-1 disrupts mismatch repair complex formation, interferes with MutSalpha recruitment on mismatch and inhibits mismatch repair through interacting with PCNA. *Oncogene.* 2013:1–13.

Figure 1. Schematic illustration of how unrepaired replication of majority of oxidized DNA base lesions cause irreversible mutations

(A) Common oxidized base modifications. (B), Illustration of replication of various base lesions in template strand, which cause mutations except for 8-oxo-G, where a mis-incorporated A, is reversed by MYH, followed by OGG1-mediated removal of 8-oxo-G.

Figure 2. A model for replication-associated progeny strand versus template strand repair
(A) Progeny strand specific post-replicative repair: Mismatch repair protein MYH recruited by PCNA at the replication fork removes A mis-incorporated opposite 8-oxo-G in the template, followed by gap filling with C. 8-oxo-G is subsequently repaired through BER initiated by OGG1. In absence of such post-replicative repair of the progeny strand, T could be incorporated during replication of the progeny strand, thus fixing the C:G to A:T transversion, **(B) Template-strand specific pre-replicative repair:** NEIL1, as part of the replication complex, acts as a ‘cow-catcher’ for surveillance of the template strand, prior to DNA synthesis. On encountering a lesion, NEIL1 non-productively binds the oxidized base in RPA coated single strand template to stall Pol δ . Subsequent fork regression brings the lesion back in the parent duplex segment, which is repaired by NEIL1 and replication proteins. On the other hand, Pol ι may correctly bypass the lesion followed by its repair through BER.

Figure 3. Ingenuity Pathway Analysis (QIAGEN) of accessory proteins that interact and/or stimulate various DNA repair and replication proteins and chromatin modification factors (See Table.1. for references derived from the IPA analysis).

Figure 4.

PONDR-FIT analysis for determining intrinsic disorder in the accessory proteins – XRCC1, hnRNP-U, YB-1, and HMGB1 and (www.disprot.org/pondr-fit.php). AS – active site, APD – alanine/proline rich domain, C – C terminal, CD – catalytic domain, CRS – cytoplasmic retention domain, CSD – cold shock domain, CTD – C terminal domain, N – N terminal, NTD – N terminal domain, NLS – nuclear localization signal, SAR – scaffold associated region, RGG – arginine-glycine-glycine domain, ZnF – zinc finger

Table 1

Roles of scaffold factors - XRCC1 and PARP1, accessory proteins – HMGB1, hnRNP-U and YB-1 and clamp 9-1-1 in interacting with and/or stimulating various DNA repair and replication proteins and chromatin modification factors with their corresponding references (derived from IPA analysis, Fig 3).

Accessory Protein	BER/SSBR Protein	Interactive Roles
HMGB1	FEN1	Stimulates FEN1 activity and promotes Pol β mediated LP-BER. [139] [142]
	APE1	Stimulates APE1 mediated incision at AP sites and enhance CAG repeat expansion [139] [142].
	MSH2	Cooperates with MSH2/MSH3 to stabilize hairpins and stimulate FEN1 “alternate cleavage” [179,141].
	ACF/CHRAC	Binds with distorted/damaged DNA and stimulates CHRAC- and ACF-mediated nucleosome remodeling [143] [144].
PARP1	NEIL1, OGG1	Physically interacts with DNA glycosylases NEIL1 and OGG1 to inhibit their incision activities; OGG1 stimulates poly-ADP-ribosylation activity of PARP1 [110] [180].
	APTX	Helps in recruitment of APTX at SSBs at blocked termini [181].
	FEN1	PARP1 inhibition reduces FEN1 accumulation at DNA damage sites [182].
	PNKP	PNKP physically interacts with PARP1, through FHA domain [183].
	PCNA	Regulates function of PCNA during replication of damaged DNA site [184]
	Pol β	Stimulates Pol β activity in LP-BER [185].
	Lig3 α	Recruits Lig3 α after PARylation at DNA strand breaks and modulates its activity [186].
	WRN	Regulates activity of WRN at DNA strand breaks depending upon its PARylated state [187].
XRCC1	DNA-PK	Interacts with DNA-PK [188].
	PARP1	Recruited by PARP1 through interaction via BRCT domains which negatively regulates its activity [189].
	PNKP	Recruits PNKP and enhances its 3'-phosphatase activity [85].
	NEIL1, NEIL2, OGG1, NTH1, MPG	Recruits multiple DNA glycosylases at base damage sites. [86]
	APTX	Phosphorylated XRCC1 binds to Aprataxin via its FHA domain, enhancing stability of XRCC1 [190].
	APE1	Physically interacts with APE1 through its N-terminal region and stimulates its activity [83].
	Pol β	Interacts with Pol β via N-terminal domain and enhances BER [191,192].
	Rev1	Interacts with Rev1 for post-replication repair [88].
	Pol δ , Pol λ	Interacts with Pol δ and Pol λ [89] [90].
	Lig3 α	Stabilizes Lig3 α through interaction via BRCT domains [193,194].
	PCNA	Interacts with PCNA for G1/S-phase specific role of XRCC1 in replication- coupled repair [82,195].
	DNA-PK	Interacts with DNA-PK (via XRCC1 BRCT1 domain) and gets phosphorylated at serine 371 after IR treatment; stimulates DNA-PK activity [196].
hnRNP-U	NEIL1	Interacts with NEIL1 and enhances BER [77].
	NEIL2	Binds and stimulates NEIL2 activity [29].
	DNA-PK	DNA-PK phosphorylates hnRNP-U at Ser59 in response to DNA DSBs [127]
	PNKP	Interacts with FHA domain of PNK [183].

Accessory Protein	BER/SSBR Protein	Interactive Roles
YB-1	NEIL2	C-terminal disordered tail of YB-1 interacts with NEIL2 N-terminal region interacts and stimulates its incision activity [134].
	NTH1	Interacts with NTH1 and stimulates its DNA glycosylase and Aplyase activity [136].
	APE1	APE1 (preferably acetylated) interacts with YB-1 C-terminal disordered tail, enhancing its binding to Y-box elements but stimulation of APE1's activity couldn't be detected [72].
	Pol β	Interacts with Pol β [134].
	PCNA	Interacts with PCNA to exert its regulatory role in mismatch repair pathway [132,197].
	Lig3 α	Interacts with Lig3 α [134].
9-1-1 (Rad9- Rad1- Hus1)	NEIL1	Interacts with NEIL1 and stimulates its activity [58].
	TDG	Interacts with TDG and stimulates its activity [59].
	Pol β	Interacts with and stimulates strand displacement synthesis by Pol β but not replicative DNA polymerases, Pol α and Pol δ [60].
	FEN1	Stimulates FEN1 activity, favoring LP-BER [62].
	WRN	Interacts with WRN helicase through Rad1 subunit which has crucial role in preventing DNA damage during replication fork stalling. [56].
	LIG1	Modulates activity of Lig1 required in LP-BER [61].